Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;25(9):1296-304.
doi: 10.3346/jkms.2010.25.9.1296. Epub 2010 Aug 14.

Aldosterone modulates cell proliferation and apoptosis in the neonatal rat heart

Hyung Joo Sohn  1 , Kee Hwan Yoo, Gi Young Jang, Jang Hoon Lee, Byung Min Choi, Jung Hwa Lee, In Sun Bae, Hyung Eun Yim, Chang Sung Son, Joo Won Lee
Affiliations

Aldosterone modulates cell proliferation and apoptosis in the neonatal rat heart

Hyung Joo Sohn et al. J Korean Med Sci. 2010 Sep.

Abstract

In the present study, we investigated whether and how the mineralocorticoid receptor antagonist spironolactone affects cardiac growth and development through apoptosis and cell proliferation in the neonatal rat heart. Newborn rat pups were treated with spironolactone (200 mg/kg/d) for 7 days. The cell proliferation was studied by PCNA immunostaining. The treatment with spironolactone decreased proliferating myocytes by 32% (P<0.05), and reduced myocytes apoptosis by 29% (P<0.05). Immunoblot and immunohistochemistry for the expression of p38, p53, clusterin, TGF-beta2, and extracellular signal-regulated kinase were performed. In the spironolactone group, p38, p53, clusterin, and TGF-beta2 protein expression was significantly decreased (P<0.05). These results indicate that aldosterone inhibition in the developing rat heart induces cardiac growth impairment by decreasing proliferation and apoptosis of myocytes.

Keywords: Aldosterone; Apoptosis; Cell Proliferation; Muscle Cells.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
PCNA positive proliferating cardiac myocytes in control and spironolactone group. (A, B) Immunohistochemical staining for PCNA in both groups demonstrates that proliferating myocytes (arrows) in the S group (B) are less than those in control group (A) (bar=25 µm). (C) Number of PCNA positive proliferating cells in control group (black bar) is reduced in spironolactone group (white bar), measured by counting 50 areas, 25×25 µm, *P<0.05.
Fig. 2
Fig. 2
Distribution of apoptotic cells in the myocardium. (A, B) Apoptotic cells (arrows) in the S group (B) are less than those in control group (A) (bar=25 µm). (C) Number of apoptotic cells in control group (black bar) is reduced in spironolactone group (white bar), measured by counting 50 areas, 25×25 µm, *P<0.05.
Fig. 3
Fig. 3
Representative expressions of p38 mRNA and protein. (A) In immunoblot analysis, p38 mRNA amount is similar between the control and S groups. (B) p38/tubulin protein expression is decreased significantly in the S group compared with the control group, *P<0.05.
Fig. 4
Fig. 4
Representative expressions of p53 mRNA and protein. (A) In immunoblot analysis, p53 mRNA amount is similar between the control and S groups. (B) p53/tubulin protein expression is decreased significantly in the S group compared with the control group, *P<0.05.
Fig. 5
Fig. 5
Representative expressions of clusterin mRNA and protein. (A) In immunoblot analysis, clusterin mRNA amount is similar between the control and S groups. (B) clusterin/tubulin protein expression is decreased significantly in the S group compared with the control group, *P<0.05.
Fig. 6
Fig. 6
Representative expressions of TGF β-2 mRNA (A) and protein (B) are reduced in the developing rat heart of the control and S groups, *P<0.05.
Fig. 7
Fig. 7
TGF β-1 protein expression in the developing rat heart. There is no difference between the control and S groups.
Fig. 8
Fig. 8
Representative expressions of ERK-1 (A) and ERK-2 proteins (B) are similar in the developing rat heart of the control and S groups.
Fig. 9
Fig. 9
JNK-2 protein expression in the developing rat heart. There is no difference between the control and S groups.
See this image and copyright information in PMC

References

    1. Choi JH, Yoo KH, Cheon HW, Kim KB, Hong YS, Lee JW, Kim SK, Kim CH. Angiotensin converting enzyme inhibition decreases cell turnover in the neonatal rat heart. Pediatr Res. 2002;52:325–332. - PubMed
    1. Burniston JG, Saini A, Tan LB, Goldspink DF. Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo. J Mol Cell Cardiol. 2005;39:395–399. - PubMed
    1. Veliotes DG, Woodiwiss A, Deftereos DA, Gray D, Osadchii O, Norton GR. Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by beta-adrenoreceptor activation. Hypertension. 2005;45:914–920. - PubMed
    1. Wang W, McClain JM, Zucker IH. Aldosterone reduces baroreceptor discharge in the dog. Hypertension. 1992;19:270–277. - PubMed
    1. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol. 2005;186:1–20. - PubMed

MeSH terms

Substances